Literature DB >> 33633218

Correlation between circulating interleukin-18 level and systemic lupus erythematosus: a meta-analysis.

Mengmeng Xiang1, Yang Feng2,3, Yilun Wang1, Jie Wang1, Zhixiong Zhang1, Jun Liang4, Jinhua Xu1,5.   

Abstract

This study is a meta-analysis aimed at pooling reported data and clarifying the association between circulating level of interleukin-18 and systemic lupus erythematosus (SLE). We searched medical databases including Medline/Pubmed, Embase, Scopus, The Cochrane Library, and Web of Science thoroughly to obtain all related articles published before July 15th, 2020. We pooled computed standardized mean difference (SMD) and its 95% confidence interval using STATA 13.0 and exhibited in the form of forest graph. Meta-regression and subgroup analysis were also performed to explore the source of heterogeneity. Publication bias was first evaluated by the symmetry of the funnel plot and then Egger's linear regression test. Thirty eligible studies from eighteen regions were finally included and the relevant data from these studies were pooled. The analysis results displayed that SLE patients showed a significantly higher level of circulating IL-18 level in comparison with healthy controls (SMD = 1.56, 95% CI [1.20-1.93]; I2 = 94.9%, p < 0.01). The conclusion was equally applicable in subgroups divided based on sample type, mean age, disease duration, and testing method. Patients with SLEDAI score higher than five, or who were Asian, White, Arab, or mixed ethnicity had an elevated level of IL-18, while the others didn't. This meta-analysis has elucidated that compared with healthy people, the circulating level of IL-18 is considerably higher in SLE patients, which indicates the underlying role of IL-18 in SLE pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33633218      PMCID: PMC7907126          DOI: 10.1038/s41598-021-84170-4

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  44 in total

1.  Quantifying heterogeneity in a meta-analysis.

Authors:  Julian P T Higgins; Simon G Thompson
Journal:  Stat Med       Date:  2002-06-15       Impact factor: 2.373

2.  Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses.

Authors:  Andreas Stang
Journal:  Eur J Epidemiol       Date:  2010-07-22       Impact factor: 8.082

Review 3.  SLE: translating lessons from model systems to human disease.

Authors:  Ram Raj Singh
Journal:  Trends Immunol       Date:  2005-09-09       Impact factor: 16.687

4.  Association of IL-18 polymorphisms with rheumatoid arthritis: a meta-analysis.

Authors:  L L Li; X F Deng; J P Li; N Ning; X L Hou; J L Chen
Journal:  Genet Mol Res       Date:  2016-01-22

5.  Association between interleukin-18 polymorphisms and systemic lupus erythematosus: a meta-analysis.

Authors:  Gwan Gyu Song; Sung Jae Choi; Jong Dae Ji; Young Ho Lee
Journal:  Mol Biol Rep       Date:  2012-12-14       Impact factor: 2.316

6.  Serum levels of IL-18 in Iranian females with systemic lupus erythematosus.

Authors:  Miramir Aghdashi; Sasan Aribi; Siamak Salami
Journal:  Med Arch       Date:  2013

7.  Serum cytokine profile in patients with active lupus nephritis.

Authors:  Katrin Franzika Koenig; Isabel Groeschl; Satu Sinikka Pesickova; Vladimir Tesar; Ute Eisenberger; Marten Trendelenburg
Journal:  Cytokine       Date:  2012-07-28       Impact factor: 3.861

8.  Circulating angiogenesis inhibitor endostatin and positive endothelial growth regulators in patients with systemic lupus erythematosus.

Authors:  E Robak; A Woźniacka; A Sysa-Jedrzejowska; H Stepień; T Robak
Journal:  Lupus       Date:  2002       Impact factor: 2.911

9.  Interleukin-18 promoter gene polymorphisms in Chinese patients with systemic lupus erythematosus: association with CC genotype at position -607.

Authors:  Qian Xu; Soe Kyaw Tin; Suppiah Paramalingam Sivalingam; Julian Thumboo; Dow Rhoon Koh; Kok Yong Fong
Journal:  Ann Acad Med Singapore       Date:  2007-02       Impact factor: 2.473

10.  Increased serum β2-microglobulin is associated with clinical and immunological markers of disease activity in systemic lupus erythematosus patients.

Authors:  M-L F Hermansen; L Hummelshøj; D Lundsgaard; L Hornum; P Keller; J Fleckner; B Fox; L K Poulsen; S Jacobsen
Journal:  Lupus       Date:  2012-05-10       Impact factor: 2.911

View more
  6 in total

1.  Identification of CDK2-Related Immune Forecast Model and ceRNA in Lung Adenocarcinoma, a Pan-Cancer Analysis.

Authors:  Ting-Ting Liu; Rui Li; Chen Huo; Jian-Ping Li; Jie Yao; Xiu-Li Ji; Yi-Qing Qu
Journal:  Front Cell Dev Biol       Date:  2021-07-30

2.  Serum interleukin-18 and its relationship with subclinical atherosclerosis in systemic lupus erythematosus.

Authors:  Zahra Rezaieyazdi; Mina AkbariRad; Nayyereh Saadati; Masoumeh Salari; Reza Orang; Sima Sedighi; Habibollah Esmaily; Mahmoud Reza Azarpazhooh; Abdollah Firoozi; Ensieh Akbarpour
Journal:  ARYA Atheroscler       Date:  2021-11

3.  Inflammation-Related LncRNAs Signature for Prognosis and Immune Response Evaluation in Uterine Corpus Endometrial Carcinoma.

Authors:  Hongmei Gu; Jiahang Song; Yizhang Chen; Yichun Wang; Xiaofang Tan; Hongyu Zhao
Journal:  Front Oncol       Date:  2022-06-02       Impact factor: 5.738

Review 4.  Cytokines as Biomarkers in Systemic Lupus Erythematosus: Value for Diagnosis and Drug Therapy.

Authors:  Helena Idborg; Vilija Oke
Journal:  Int J Mol Sci       Date:  2021-10-20       Impact factor: 5.923

Review 5.  Interleukin-18 Binding Protein in Immune Regulation and Autoimmune Diseases.

Authors:  Seung Yong Park; Yasmin Hisham; Hyun Mu Shin; Su Cheong Yeom; Soohyun Kim
Journal:  Biomedicines       Date:  2022-07-20

Review 6.  Interleukin-18 cytokine in immunity, inflammation, and autoimmunity: Biological role in induction, regulation, and treatment.

Authors:  Stella Amarachi Ihim; Sharafudeen Dahiru Abubakar; Zeineb Zian; Takanori Sasaki; Mohammad Saffarioun; Shayan Maleknia; Gholamreza Azizi
Journal:  Front Immunol       Date:  2022-08-11       Impact factor: 8.786

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.